Shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) were up 6.5% during trading on Wednesday . The company traded as high as $15.84 and last traded at $15.83, with a volume of 328,113 shares changing hands. The stock had previously closed at $14.86.

A number of analysts have recently commented on BLCM shares. SunTrust Banks Inc. started coverage on shares of Bellicum Pharmacueticals in a report on Thursday, June 2nd. They set a “buy” rating and a $20.00 target price on the stock. Piper Jaffray Cos. restated a “buy” rating on shares of Bellicum Pharmacueticals in a report on Saturday, July 9th. Finally, Zacks Investment Research upgraded shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a report on Monday, July 11th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $27.50.

The stock has a 50-day moving average price of $13.29 and a 200 day moving average price of $11.14. The stock’s market cap is $442.00 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.07. On average, equities analysts expect that Bellicum Pharmacueticals Inc. will post ($2.22) earnings per share for the current year.

In related news, VP Ken Moseley sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total transaction of $195,000.00. Following the completion of the sale, the vice president now directly owns 15,196 shares in the company, valued at $197,548. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Annemarie Moseley sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total value of $325,000.00. Following the sale, the chief operating officer now owns 18,486 shares of the company’s stock, valued at $240,318. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley boosted its stake in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned about 1.61% of Bellicum Pharmacueticals worth $8,653,000 as of its most recent SEC filing.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.